Related Experiment Videos
Reconstructing Longitudinal Medication Trajectories from Integrated National Claims and Clinical Data Warehouse Data:
Mathilde Bories1, Pascal Le Corre2,3, Aurélie Bannay4
1CHU Rennes, INSERM, LTSI-UMR 1099, Univ Rennes, 35000 Rennes, France.
None:
Medication data are fragmented across national and hospital databases, limiting consistent longitudinal assessment of drug exposure. Using data from the multicentre HUGOSHARE infrastructure linking university hospitals in Western France to the French national claims (SNDS), we quantified longitudinal medication exposure in oncology patients (2015-2019). Drug identifiers were harmonised via Thériaque (CIP/UCD to ATC level 5) to enable cross-source comparability. Among 57,960 patients, the prevalence of polypharmacy (≥5 drugs/day) was 34% pre-admission, 43% during hospitalisation, and 16% post-discharge; hyper-polypharmacy (≥10 drugs/day) was 8%, 35%, and 4%, respectively. This study demonstrates the feasibility of scalable, interoperable medication analytics across care transitions and opens perspectives for monitoring drug-related risks and cumulative exposure in real-world data.
Related Concept Videos
Cancer Survival Analysis
Longitudinal Studies
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Therapeutic Drug Monitoring: Affecting Factors
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...